C12N 2760/20222
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/20222 (New viral proteins or individual genes, new structural or functional aspects of) appears on 154 US grants and 282 published applications in this corpus.
Search patents in C12N- Granted patents
- 154
- Published applications
- 282
- Assignees
- 163
- Inventors
- 561
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 6 | 2 |
| 2002 | 9 | 3 |
| 2003 | 5 | 13 |
| 2004 | 4 | 6 |
| 2005 | 2 | 7 |
| 2006 | 2 | 3 |
| 2007 | 3 | 6 |
| 2008 | 2 | 1 |
| 2009 | 4 | 9 |
| 2010 | 3 | 10 |
| 2011 | 5 | 5 |
| 2012 | 6 | 7 |
| 2013 | 3 | 5 |
| 2014 | 5 | 7 |
| 2015 | 2 | 7 |
| 2016 | 5 | 8 |
| 2017 | 11 | 11 |
| 2018 | 11 | 4 |
| 2019 | 4 | 6 |
| 2020 | 6 | 12 |
| 2021 | 4 | 10 |
| 2022 | 3 | 11 |
| 2023 | 7 | 20 |
| 2024 | 6 | 41 |
| 2025 | 19 | 36 |
| 2026 | 4 | 32 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors15 Sep 2026US 12,734,202 B2Joint Biosciences (Sh) Ltd.
- Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof31 Mar 2026US 12,590,321 B2Exuma Biotech Corp.
- Compositions and methods of use of oncolytic virus like vesicles17 Mar 2026US 12,577,585 B2Carogen Corporation
- Detection assays for coronavirus neutralizing antibodies20 Jan 2026US 12,529,699 B2Regeneron Pharmaceuticals, Inc.
- Compositions for treating cancer14 Oct 2025US 12,440,564 B2Kelonia Therapeutics, Inc.
- Purification of viruses and viral like particles8 Oct 2026US 2026/0308616 A1Interius Biotherapeutics, Inc.
- Cell surface engineered of tailored therapeutic gene delivery8 Oct 2026US 2026/0308617 A1The Children’s Hospital of Philadelphia
- Modular re-targeting of rhabdoviral (g) glycoproteins from their natural receptors24 Sep 2026US 2026/0285912 A1Vyriad, Inc.
- Vector production24 Sep 2026US 2026/0286391 A1Fondazione Telethon Ets
- Pseudotyped retroviral vector particle with anti-cd3 display24 Sep 2026US 2026/0286392 A1Miltenyi Biotec GmbH
Most cited
By later US patents
- Vector and method of use for nucleic acid delivery to non-dividing cells323US 6,013,516 AThe Salk Institute for Biological Studies · 2000
- Composition and methods for transfecting eukaryotic cells122US 5,578,475 ALife Technologies Corporation · 1996
- Stranded RNA virus particles108US 5,789,229 AThe UAB Research Foundation · 1998
- Viruses with recombinant surface proteins96US 4,593,002 AThe Salk Institute Biotechnology/Industrial Associates, Inc. · 1986
- Composition and methods for transfecting eukaryotic cells84US 6,020,202 ALife Technologies Corporation · 2000